Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer

Yu Mi Jo, Joon-Young Song, In Sook Hwang, Jacob Lee, Sang Cheul Oh, Jun Suk Kim, Sung Ran Kim, Woo Joo Kim, Hee-Jin Cheong

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Influenza vaccine is considered to reduce influenza- related morbidity and mortality in patients with underlying chronic medical conditions. Because of fear of vaccine shortage during an influenza pandemic, several antigen sparing strategies have been investigated. The immuno- genicity of intradermal influenza vaccination with one half the antigenic contents was compared to that of conventional intramuscular vaccination in patients with solid cancer, and adverse events were assessed after vaccination. There was no significant difference between the injection routes in the hemagglutinin inhibition (H)response and increase in the titer of A/H1N1, A/H3N2, and B 4-6 weeks after the vaccination; seroconversion factors increased by more than 2.5-fold. Seroresponse rates were more than 40% and seroprotection rates were above 70% against all three influenza strains irrespective of the vaccination routes. No serious events were observed and local skin reactions were more frequent in the intradermal injection recipients than in the intra- muscular recipients (32.7% vs. 9.1%). This study shows that intradermal injection of one half the dose of a commercial influenza vaccine elicits immune responses comparable to those elicited by a full dose of intramuscular vaccine among cancer patients, and it can be tolerated without serious adverse reactions.

Original languageEnglish
Pages (from-to)722-727
Number of pages6
JournalJournal of Medical Virology
Volume81
Issue number4
DOIs
Publication statusPublished - 2009 Apr 1

Fingerprint

Human Influenza
Vaccination
Intradermal Injections
Influenza Vaccines
Neoplasms
Cancer Vaccines
Hemagglutinins
Pandemics
Fear
Vaccines
Morbidity
Antigens
Skin
Injections
Mortality

Keywords

  • Cancer
  • Influenza
  • Intradermal
  • Vaccine

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. / Jo, Yu Mi; Song, Joon-Young; Hwang, In Sook; Lee, Jacob; Oh, Sang Cheul; Kim, Jun Suk; Kim, Sung Ran; Kim, Woo Joo; Cheong, Hee-Jin.

In: Journal of Medical Virology, Vol. 81, No. 4, 01.04.2009, p. 722-727.

Research output: Contribution to journalArticle

@article{91710653dc744eca8dae79596ed88cfa,
title = "Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer",
abstract = "Influenza vaccine is considered to reduce influenza- related morbidity and mortality in patients with underlying chronic medical conditions. Because of fear of vaccine shortage during an influenza pandemic, several antigen sparing strategies have been investigated. The immuno- genicity of intradermal influenza vaccination with one half the antigenic contents was compared to that of conventional intramuscular vaccination in patients with solid cancer, and adverse events were assessed after vaccination. There was no significant difference between the injection routes in the hemagglutinin inhibition (H)response and increase in the titer of A/H1N1, A/H3N2, and B 4-6 weeks after the vaccination; seroconversion factors increased by more than 2.5-fold. Seroresponse rates were more than 40{\%} and seroprotection rates were above 70{\%} against all three influenza strains irrespective of the vaccination routes. No serious events were observed and local skin reactions were more frequent in the intradermal injection recipients than in the intra- muscular recipients (32.7{\%} vs. 9.1{\%}). This study shows that intradermal injection of one half the dose of a commercial influenza vaccine elicits immune responses comparable to those elicited by a full dose of intramuscular vaccine among cancer patients, and it can be tolerated without serious adverse reactions.",
keywords = "Cancer, Influenza, Intradermal, Vaccine",
author = "Jo, {Yu Mi} and Joon-Young Song and Hwang, {In Sook} and Jacob Lee and Oh, {Sang Cheul} and Kim, {Jun Suk} and Kim, {Sung Ran} and Kim, {Woo Joo} and Hee-Jin Cheong",
year = "2009",
month = "4",
day = "1",
doi = "10.1002/jmv.21186",
language = "English",
volume = "81",
pages = "722--727",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer

AU - Jo, Yu Mi

AU - Song, Joon-Young

AU - Hwang, In Sook

AU - Lee, Jacob

AU - Oh, Sang Cheul

AU - Kim, Jun Suk

AU - Kim, Sung Ran

AU - Kim, Woo Joo

AU - Cheong, Hee-Jin

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Influenza vaccine is considered to reduce influenza- related morbidity and mortality in patients with underlying chronic medical conditions. Because of fear of vaccine shortage during an influenza pandemic, several antigen sparing strategies have been investigated. The immuno- genicity of intradermal influenza vaccination with one half the antigenic contents was compared to that of conventional intramuscular vaccination in patients with solid cancer, and adverse events were assessed after vaccination. There was no significant difference between the injection routes in the hemagglutinin inhibition (H)response and increase in the titer of A/H1N1, A/H3N2, and B 4-6 weeks after the vaccination; seroconversion factors increased by more than 2.5-fold. Seroresponse rates were more than 40% and seroprotection rates were above 70% against all three influenza strains irrespective of the vaccination routes. No serious events were observed and local skin reactions were more frequent in the intradermal injection recipients than in the intra- muscular recipients (32.7% vs. 9.1%). This study shows that intradermal injection of one half the dose of a commercial influenza vaccine elicits immune responses comparable to those elicited by a full dose of intramuscular vaccine among cancer patients, and it can be tolerated without serious adverse reactions.

AB - Influenza vaccine is considered to reduce influenza- related morbidity and mortality in patients with underlying chronic medical conditions. Because of fear of vaccine shortage during an influenza pandemic, several antigen sparing strategies have been investigated. The immuno- genicity of intradermal influenza vaccination with one half the antigenic contents was compared to that of conventional intramuscular vaccination in patients with solid cancer, and adverse events were assessed after vaccination. There was no significant difference between the injection routes in the hemagglutinin inhibition (H)response and increase in the titer of A/H1N1, A/H3N2, and B 4-6 weeks after the vaccination; seroconversion factors increased by more than 2.5-fold. Seroresponse rates were more than 40% and seroprotection rates were above 70% against all three influenza strains irrespective of the vaccination routes. No serious events were observed and local skin reactions were more frequent in the intradermal injection recipients than in the intra- muscular recipients (32.7% vs. 9.1%). This study shows that intradermal injection of one half the dose of a commercial influenza vaccine elicits immune responses comparable to those elicited by a full dose of intramuscular vaccine among cancer patients, and it can be tolerated without serious adverse reactions.

KW - Cancer

KW - Influenza

KW - Intradermal

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=62849106688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62849106688&partnerID=8YFLogxK

U2 - 10.1002/jmv.21186

DO - 10.1002/jmv.21186

M3 - Article

VL - 81

SP - 722

EP - 727

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 4

ER -